Serology testing in the COVID-19 pandemic response.
Antibodies, Viral
/ blood
Betacoronavirus
/ genetics
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
Contact Tracing
/ methods
Coronavirus Infections
/ diagnosis
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Pandemics
/ prevention & control
Pneumonia, Viral
/ diagnosis
RNA, Viral
/ analysis
SARS-CoV-2
Time Factors
Triage
/ methods
Virus Shedding
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
11
05
2020
revised:
04
06
2020
accepted:
04
06
2020
pubmed:
21
7
2020
medline:
10
9
2020
entrez:
21
7
2020
Statut:
ppublish
Résumé
The collapse of global cooperation and a failure of international solidarity have led to many low-income and middle-income countries being denied access to molecular diagnostics in the COVID-19 pandemic response. Yet the scarcity of knowledge on the dynamics of the immune response to infection has led to hesitation on recommending the use of rapid immunodiagnostic tests, even though rapid serology tests are commercially available and scalable. On the basis of our knowledge and understanding of viral infectivity and host response, we urge countries without the capacity to do molecular testing at scale to research the use of serology tests to triage symptomatic patients in community settings, to test contacts of confirmed cases, and in situational analysis and surveillance. The WHO R&D Blue Print expert group identified eight priorities for research and development, of which the highest is to mobilise research on rapid point-of-care diagnostics for use at the community level. This research should inform control programmes of the required performance and utility of rapid serology tests, which, when applied specifically for appropriate public health measures to then be put in place, can make a huge difference.
Identifiants
pubmed: 32687805
pii: S1473-3099(20)30517-X
doi: 10.1016/S1473-3099(20)30517-X
pmc: PMC7367660
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
RNA, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e245-e249Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Int J Infect Dis. 2020 May;94:49-52
pubmed: 32251798
Lancet. 2020 May 16;395(10236):1527-1529
pubmed: 32353328
Cochrane Database Syst Rev. 2020 Apr 8;4:CD013574
pubmed: 32267544
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
J Travel Med. 2020 May 18;27(3):
pubmed: 32167146
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Nature. 2020 Apr;580(7805):565
pubmed: 32346145
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
Lancet. 2020 Mar 28;395(10229):1039-1046
pubmed: 32192580
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Science. 2020 May 8;368(6491):
pubmed: 32234805
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
Lancet. 2020 May 23;395(10237):1595-1598
pubmed: 32380041
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Lancet Infect Dis. 2020 Jul;20(7):809-815
pubmed: 32330439